Press Releases

Oct 22, 2015 • 8:05 AM EDT Matinas BioPharma Selected to Present at Cavendish Global Health Impact Forum

Oct 14, 2015 • 7:05 AM EDT Matinas BioPharma to Present at the 14th Annual BIO Investor Forum on October 20, 2015

Oct 10, 2015 • 8:00 AM EDT Matinas BioPharma Presents Preclinical PK and Efficacy Data of Encochleated Atovaquone in Murine Model at IDWeek 2015

Oct 5, 2015 • 7:00 AM EDT Matinas BioPharma Receives Institutional Review Board Approval to Commence NIH-Sponsored Phase 2a Study With MAT2203 – An Orally Delivered, Encochleated Formulation of Amphotericin B –

Sep 19, 2015 • 2:00 PM EDT Matinas BioPharma Presents Pre-clinical Data Showing Anti-bacterial Activity of MAT2501 - Encochleated Amikacin - Against Mycobacterium Avium Lung Infections at ICAAC/ICC 2015

Sep 18, 2015 • 3:00 PM EDT Matinas BioPharma's MAT2203 -- Encochleated Formulation of Amphotericin B -- Shows Potential to Target and Penetrate Tissue Infected With Invasive Candidiasis in Data Presented at ICAAC/ICC 2015

Sep 17, 2015 • 7:00 AM EDT Matinas BioPharma Appoints International Expert and Thought Leader on Invasive Fungal Infections Peter G. Pappas, M.D., FACP, to Scientific Advisory Board

Sep 2, 2015 • 7:05 AM EDT Matinas BioPharma to Present at the 17th Annual Rodman & Renshaw Global Investment Conference on September 9, 2015

Sep 1, 2015 • 7:00 AM EDT Matinas BioPharma Appoints Cochleate Technology Pioneer Raphael J. Mannino, Ph.D., as Senior Vice President and Chief Technology Officer

Aug 18, 2015 • 7:00 AM EDT Matinas BioPharma's Lead Antifungal Product Candidate MAT2203 Granted QIDP and Fast Track Designations by U.S. FDA